---
document_datetime: 2025-06-26 11:56:48
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pavblu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pavblu-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2979991
conversion_datetime: 2025-12-26 11:18:33.374094
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## PAVBLU

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                           |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|---------------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 26/06/2025                          |                                             | SmPC,                            | To update section 4.8 of the SmPC and PL in order |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000276431   | Labelling and PL   | to add `scleritis' to the list of adverse drug reactions (ADRs) with frequency of `0.2 cases per 1 million injections' based on pharmacovigilance data. The change follows assessment of the same change to the reference product, Eylea. Additionally, the MAH took the opportunity to add a warning for polysorbate in the SmPC and the PL in line with the EC Excipient Guideline.   |
|---------------------|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|